GLP1R and type 2 diabetes mellitus: Novel non-insulin antidiabetic agents, especially SGLT-2 inhibitors and GLP1-RAs, offer substantial benefits, including weight loss and alteration of the underlying pathophysiology of type 2 diabetes, but also require screening and monitoring for adverse drug events.